Oral HIF-PH Inhibitors for the Treatment of Renal Anemia in CKD Non-Dialysis and Dialysis: How Will U.S. Physicians and Payers Respond to This Novel Class? | Physician & Payer Forum | US | 2014

Renal anemia and hyperphosphatemia, or elevated serum phosphorous, are two primary complications of chronic kidney disease (CKD) that are treated with erythropoiesis-stimulating agents (ESAs) and phosphate binders, respectively. The U.S. market for renal anemia drugs is poised to expand owing to the growing size of the CKD non-dialysis (CKD-ND) and dialysis patient populations, as well as the expected launches of novel therapies such as oral hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors to treat renal anemia (i.e., roxadustat, AKB-6548, GSK-1278863A, and molidustat). This report examines the dynamics that will limit or promote market access for emerging oral HIF-PH inhibitors in the pipeline as new drug launches are expected as early as 2018. We analyze physician prescribing of ESAs, future prescribing practices, the impact and uptake of oral HIF-PH inhibitors on current therapy use, and formulary decision making for current and emerging agents, among other topics.

Login to access report